The European Commission has awarded 3.4 Million Euro under the Horizon 2020 programme to a new Marie Curie European Training Network – CARTNET, “Combating Antimicrobial Resistance Training Network”, in which Oxford Drug Design is a consortium partner.
CARTNET brings together 13 academic and industrial research groups from 8 countries and will contribute to delivering solutions to the challenges of bacterial infectious diseases that affect both humans and animals.

This award is further recognition of the innovation that Oxford Drug Design is bringing to the search for new antibacterials. Oxford Drug Design will use its state-of-the-art drug discovery tools to optimizing existing inhibitors of the novel antibacterial target, histidine kinase, and the discovery of new ones. The ultimate aim is to develop antibacterial compounds with a good resistance profile as candidate novel antibiotics.

The project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No 765147.